NURS 5334/NURS5334
‘/ Stuvia:thebest studymaterialfromyourfellowstudents
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
University of Texas, ArlingtonNURS 5334/NURS5334: Quiz 2 ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
40 Questions and Answers (explained) | 100% correct 2025/26.
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
Section1:Pharmacokinetics&Pharmacodynamics ‘/ ‘/ ‘/ ‘/
(Questions 1–12)
‘/ ‘/
1. A patient with end-stage renal disease (eGFR <15 mL/min) is prescribed a medication
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
that is 70% renally excreted. The nurse practitioner should anticipate:
‘/ ‘/ ‘/ ‘ / ‘/ ‘/ ‘/ ‘/ ‘ / ‘/
A. Increasing the dose by 50% ‘/ ‘/ ‘/ ‘/
B. Decreasing the dosing frequency ‘ / ‘ / ‘ /
C. Changing to a prodrug ‘/ ‘/ ‘/
D. Adding a diuretic to enhance excretion ‘ / ‘ / ‘/ ‘ / ‘/
Answer: B — Reduced renal clearance leads to drug accumulation. Decreasing frequency
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
maintains therapeutic levels without toxicity .
‘/ ‘/ ‘/ ‘/ ‘/ ‘/
2. Which cytochrome P450 enzyme is most commonly involved in clinically
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
significant drug-drug interactions?
‘/ ‘/ ‘/
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C9
Answer: C — CYP3A4 metabolizes approximately 50% of marketed drugs and is highly
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
susceptible to inhibition and induction .
‘/ ‘/ ‘/ ‘/ ‘/ ‘/
See all study documents for NURS 5334/NURS5334
‘/ ‘/ ‘/ ‘/ ‘/ ‘/
, NURS 5334/NURS5334
‘/ Stuvia:thebest studymaterialfromyourfellowstudents
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
3. A drug with high first-pass effect is given orally. The NP understands that:
‘/ ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘/ ‘ / ‘/ ‘/ ‘ /
A. The drug will have increased bioavailability
‘/ ‘ / ‘/ ‘/ ‘ /
B. The drug must be given via a non-oral route to avoid extensive hepatic metabolism
‘/ ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘/ ‘ / ‘/ ‘ / ‘/
C. Gastric pH will alter absorption significantly
‘/ ‘ / ‘ / ‘ / ‘ /
D. Protein binding will be decreased ‘/ ‘ / ‘ / ‘/
Answer: B — High first-pass effect means the liver metabolizes much of the drug before it
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
reaches systemic circulation .
‘/ ‘/ ‘/ ‘/
4. A patient takes warfarin. Starting rifampin (a potent CYP inducer) will likely:
‘/ ‘ / ‘/ ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘ /
A. Increase INR and bleeding risk ‘/ ‘ / ‘ / ‘ /
B. Decrease INR and reduce anticoagulant effect ‘ / ‘ / ‘ / ‘ / ‘ /
C. Have no effect on INR
‘/ ‘/ ‘/ ‘/
D. Cause warfarin toxicity ‘ / ‘ /
Answer: B — Rifampin induces CYP enzymes that metabolize warfarin, reducing its
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
anticoagulant effect .
‘/ ‘/ ‘/
5. What is the study of drug movement throughout the body called?
‘ / ‘ / ‘/ ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘ /
A. Pharmacodynamics
B. Pharmacokinetics
C. Pharmacotherapeutics
D. Pharmacogenomics
Answer: B — Pharmacokinetics encompasses absorption, distribution, metabolism, and
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
excretion (ADME) .
‘/ ‘/ ‘/
6. A patient with liver cirrhosis has reduced synthesis of albumin. The NP should
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
anticipate that a highly protein-bound drug will have:
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
‘/ Stuvia:thebest studymaterialfromyourfellowstudents
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
University of Texas, ArlingtonNURS 5334/NURS5334: Quiz 2 ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
40 Questions and Answers (explained) | 100% correct 2025/26.
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
Section1:Pharmacokinetics&Pharmacodynamics ‘/ ‘/ ‘/ ‘/
(Questions 1–12)
‘/ ‘/
1. A patient with end-stage renal disease (eGFR <15 mL/min) is prescribed a medication
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
that is 70% renally excreted. The nurse practitioner should anticipate:
‘/ ‘/ ‘/ ‘ / ‘/ ‘/ ‘/ ‘/ ‘ / ‘/
A. Increasing the dose by 50% ‘/ ‘/ ‘/ ‘/
B. Decreasing the dosing frequency ‘ / ‘ / ‘ /
C. Changing to a prodrug ‘/ ‘/ ‘/
D. Adding a diuretic to enhance excretion ‘ / ‘ / ‘/ ‘ / ‘/
Answer: B — Reduced renal clearance leads to drug accumulation. Decreasing frequency
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
maintains therapeutic levels without toxicity .
‘/ ‘/ ‘/ ‘/ ‘/ ‘/
2. Which cytochrome P450 enzyme is most commonly involved in clinically
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
significant drug-drug interactions?
‘/ ‘/ ‘/
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C9
Answer: C — CYP3A4 metabolizes approximately 50% of marketed drugs and is highly
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
susceptible to inhibition and induction .
‘/ ‘/ ‘/ ‘/ ‘/ ‘/
See all study documents for NURS 5334/NURS5334
‘/ ‘/ ‘/ ‘/ ‘/ ‘/
, NURS 5334/NURS5334
‘/ Stuvia:thebest studymaterialfromyourfellowstudents
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
3. A drug with high first-pass effect is given orally. The NP understands that:
‘/ ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘/ ‘ / ‘/ ‘/ ‘ /
A. The drug will have increased bioavailability
‘/ ‘ / ‘/ ‘/ ‘ /
B. The drug must be given via a non-oral route to avoid extensive hepatic metabolism
‘/ ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘/ ‘ / ‘/ ‘ / ‘/
C. Gastric pH will alter absorption significantly
‘/ ‘ / ‘ / ‘ / ‘ /
D. Protein binding will be decreased ‘/ ‘ / ‘ / ‘/
Answer: B — High first-pass effect means the liver metabolizes much of the drug before it
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
reaches systemic circulation .
‘/ ‘/ ‘/ ‘/
4. A patient takes warfarin. Starting rifampin (a potent CYP inducer) will likely:
‘/ ‘ / ‘/ ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘ /
A. Increase INR and bleeding risk ‘/ ‘ / ‘ / ‘ /
B. Decrease INR and reduce anticoagulant effect ‘ / ‘ / ‘ / ‘ / ‘ /
C. Have no effect on INR
‘/ ‘/ ‘/ ‘/
D. Cause warfarin toxicity ‘ / ‘ /
Answer: B — Rifampin induces CYP enzymes that metabolize warfarin, reducing its
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
anticoagulant effect .
‘/ ‘/ ‘/
5. What is the study of drug movement throughout the body called?
‘ / ‘ / ‘/ ‘ / ‘ / ‘ / ‘ / ‘ / ‘ / ‘ /
A. Pharmacodynamics
B. Pharmacokinetics
C. Pharmacotherapeutics
D. Pharmacogenomics
Answer: B — Pharmacokinetics encompasses absorption, distribution, metabolism, and
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
excretion (ADME) .
‘/ ‘/ ‘/
6. A patient with liver cirrhosis has reduced synthesis of albumin. The NP should
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
anticipate that a highly protein-bound drug will have:
‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/ ‘/
